|
1
|
Civitareale D, Lonigro R, Sinclair AJ and
Di Lauro R: A thyroid-specific nuclear protein essential for
tissue-specific expression of the thyroglobulin promoter. EMBO J.
8:2537–2542. 1989.PubMed/NCBI
|
|
2
|
Guazzi S, Price M, De Felice M, Damante G,
Mattei MG and DiLauro R: Thyroid nuclear factor 1 (TTF-1) contains
a homeodomain and displays a novel DNA binding specificity. EMBO J.
9:3631–3639. 1990.PubMed/NCBI
|
|
3
|
Ordóñez NG: Value of thyroid transcription
factor-1 immunostaining in distinguishing small cell lung
carcinomas from other small cell carcinomas. Am J Surg Pathol.
24:1217–1223. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen J, Wall NR, Kocher K, Duclos N,
Fabbro D, Neuberg D, Griffin JD, Shi Y and Gilliland DG: Stable
expression of small interfering RNA sensitizes TEL-PDGFbetaR to
inhibition with imatinib or rapamycin. J Clin Invest.
113:1784–1791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ziad A, Ruchala M, Breborowicz J, Gembicki
M, Sowinski J and Grzymislawski M: Immunoexpression of TTF-1 and
Ki-67 in a coexistent anaplastic and follicular thyroid cancer with
rare long-life surviving. Folia Histochem Cytobiol. 46:461–464.
2008.
|
|
6
|
Zhang P, Zuo H, Nakamura Y, Nakamura M,
Wakasa T and Kakudo K: Immunohistochemical analysis of
thyroid-specific transcription factors in thyroid tumors. Pathol
Int. 56:240–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ordóñez NG: Thyroid transcription factor-1
is a marker of lung and thyroid carcinomas. Adv Anat Pathol.
7:123–127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fenton CL, Patel A, Burch HB, Tuttle RM
and Francis GL: Nuclear localization of thyroid transcription
factor-1 correlates with serum thyrotropin activity and may be
increased in differentiated thyroid carcinomas with aggressive
clinical course. Ann Clin Lab Sci. 31:245–252. 2001.PubMed/NCBI
|
|
9
|
Barletta JA, Perner S, Iafrate AJ, Yeap
BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis
WD, et al: Clinical significance of TTF-1 protein expression and
TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med.
13(8B): 1977–1986. 2009. View Article : Google Scholar
|
|
10
|
Yamaguchi T, Hosono Y, Yanagisawa K and
Takahashi T: NKX2-1/TTF-1: An enigmatic oncogene that functions as
a double-edged sword for cancer cell survival and progression.
Cancer Cell. 23:718–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mu D: The complexity of thyroid
transcription factor 1 with both pro- and anti-oncogenic
activities. J Biol Chem. 288:24992–25000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hwang DH, Sholl LM, Rojas-Rudilla V, Hall
DL, Shivdasani P, Garcia EP, MacConaill LE, Vivero M, Hornick JL,
Kuo FC, et al: KRAS and NKX2-1 mutations in invasive mucinous
adenocarcinoma of the lung. J Thorac Oncol. 11:496–503. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takanashi Y, Tajima S, Hayakawa T,
Neyatani H and Funai K: KRAS mutation-positive bronchial surface
epithelium (BSE)-type lung adenocarcinoma with strong expression of
TTF-1: A case providing a further insight as for the role of TTF-1
in the oncogenesis. Int J Clin Exp Pathol. 8:15338–15343. 2015.
|
|
14
|
Hu Y, Hartmann A, Stoehr C, Zhang S, Wang
M, Tacha D, Montironi R, Lopez-Beltran A and Cheng L: PAX8 is
expressed in the majority of renal epithelial neoplasms: An
immunohistochemical study of 223 cases using a mouse monoclonal
antibody. J Clin Pathol. 65:254–256. 2012. View Article : Google Scholar
|
|
15
|
Laury AR, Perets R, Piao H, Krane JF,
Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, et
al: A comprehensive analysis of PAX8 expression in human epithelial
tumors. Am J Surg Pathol. 35:816–826. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ordóñez NG: Value of PAX 8 immunostaining
in tumor diagnosis: A review and update. Adv Anat Pathol.
19:140–151. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nonaka D, Tang Y, Chiriboga L, Rivera M
and Ghossein R: Diagnostic utility of thyroid transcription factors
Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol.
21:192–200. 2008.
|
|
18
|
Presta I, Arturi F, Ferretti E, Mattei T,
Scarpelli D, Tosi E, Scipioni A, Celano M, Gulino A, Filetti S, et
al: Recovery of NIS expression in thyroid cancer cells by
overexpression of Pax8 gene. BMC Cancer. 5:802005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mu D, Huang R, Li S, Ma X, Lou C and Kuang
A: Combining transfer of TTF-1 and Pax-8 gene: A potential strategy
to promote radioiodine therapy of thyroid carcinoma. Cancer Gene
Ther. 19:402–411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Antonica F, Kasprzyk DF, Opitz R, Iacovino
M, Liao XH, Dumitrescu AM, Refetoff S, Peremans K, Manto M, Kyba M,
et al: Generation of functional thyroid from embryonic stem cells.
Nature. 491:66–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dokmanovic M, Clarke C and Marks PA:
Histone deacetylase inhibitors: Overview and perspectives. Mol
Cancer Res. 5:981–989. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Slingerland M, Guchelaar HJ and Gelderblom
H: Histone deacetylase inhibitors: An overview of the clinical
studies in solid tumors. Anticancer Drugs. 25:140–149. 2014.
View Article : Google Scholar
|
|
23
|
Fortunati N, Catalano MG, Arena K,
Brignardello E, Piovesan A and Boccuzzi G: Valproic acid induces
the expression of the Na+/I− symporter and
iodine uptake in poorly differentiated thyroid cancer cells. J Clin
Endocrinol Metab. 89:1006–1009. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Furuya F, Shimura H, Suzuki H, Taki K,
Ohta K, Haraguchi K, Onaya T, Endo T and Kobayashi T: Histone
deacetylase inhibitors restore radioiodide uptake and retention in
poorly differentiated and anaplastic thyroid cancer cells by
expression of the sodium/iodide symporter thyroperoxidase and
thyroglobulin. Endocrinology. 145:2865–2875. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pugliese M, Fortunati N, Germano A, Asioli
S, Marano F, Palestini N, Frairia R, Boccuzzi G and Catalano MG:
Histone deacetylase inhibition affects sodium iodide symporter
expression and induces 131I cytotoxicity in anaplastic thyroid
cancer cells. Thyroid. 23:838–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Puppin C, D’Aurizio F, D’Elia AV,
Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei
T, et al: Effects of histone acetylation on sodium iodide symporter
promoter and expression of thyroid-specific transcription factors.
Endocrinology. 146:3967–3974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vivaldi A, Miasaki FY, Ciampi R, Agate L,
Collecchi P, Capodanno A, Pinchera A and Elisei R:
Re-differentiation of thyroid carcinoma cell lines treated with
5-Aza-2′-deoxycytidine and retinoic acid. Mol Cell Endocrinol.
307:142–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kondo T, Nakazawa T, Ma D, Niu D,
Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M and
Katoh R: Epigenetic silencing of TTF-1/NKX2-1 through DNA
hypermethylation and histone H3 modulation in thyroid carcinomas.
Lab Invest. 89:791–799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Raouane M, Desmaele D, Gilbert-Sirieix M,
Gueutin C, Zouhiri F, Bourgaux C, Lepeltier E, Gref R, Ben Salah R,
Clayman G, et al: Synthesis, characterization, and in vivo delivery
of siRNA-squalene nanoparticles targeting fusion oncogene in
papillary thyroid carcinoma. J Med Chem. 54:4067–4076. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gilbert-Sirieix M, Makoukji J, Kimura S,
Talbot M, Caillou B, Massaad C and Massaad-Massade L: Wnt/β-catenin
signaling pathway is a direct enhancer of thyroid transcription
factor-1 in human papillary thyroid carcinoma cells. PLoS One.
6:e222802011. View Article : Google Scholar
|
|
31
|
Yamazaki CA, Padovani RP, Biscolla RP,
Ikejiri ES, Marchetti RR, Castiglioni ML, Matsumura LK, Maciel RM
and Furlanetto RP: Lithium as an adjuvant in the postoperative
ablation of remnant tissue in low-risk thyroid carcinoma. Thyroid.
22:1002–1006. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Altmann A, Markert A, Askoxylakis V,
Schöning T, Jesenofsky R, Eisenhut M and Haberkorn U: Antitumor
effects of proteasome inhibition in anaplastic thyroid carcinoma. J
Nucl Med. 53:1764–1771. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Oliva J, Dedes J, Li J, French SW and
Bardag-Gorce F: Epigenetics of proteasome inhibition in the liver
of rats fed ethanol chronically. World J Gastroenterol. 15:705–712.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pohlenz J, Dumitrescu A, Zundel D, Martiné
U, Schönberger W, Koo E, Weiss RE, Cohen RN, Kimura S and Refetoff
S: Partial deficiency of thyroid transcription factor 1 produces
predominantly neurological defects in humans and mice. J Clin
Invest. 109:469–473. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vilain C, Rydlewski C, Duprez L, Heinrichs
C, Abramowicz M, Malvaux P, Renneboog B, Parma J, Costagliola S and
Vassart G: Autosomal dominant transmission of congenital thyroid
hypoplasia due to loss-of-function mutation of PAX8. J Clin
Endocrinol Metab. 86:234–238. 2001.PubMed/NCBI
|
|
36
|
Ali HM, Maksimenko A, Urbinati G, Chapuis
H, Raouane M, Desmaële D, Yasuhiro H, Harashima H, Couvreur P and
Massaad-Massade L: Effects of silencing the RET/PTC1 oncogene in
papillary thyroid carcinoma by siRNA-squalene nanoparticles with
and without fusogenic companion GALA-cholesterol. Thyroid.
24:327–338. 2014. View Article : Google Scholar
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
38
|
Urbinati G, Ali HM, Rousseau Q, Chapuis H,
Desmaële D, Couvreur P and Massaad-Massade L: Antineoplastic
effects of siRNA against TMPRSS2-ERG junction oncogene in prostate
cancer. PLoS One. 10:e01252772015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ali HM, Urbinati G, Chapuis H, Desmaele D,
Bertrand JR, Couvreur P and Massaad-Massade L: Effects of siRNA on
RET/PTC3 junction oncogene in papillary thyroid carcinoma: From
molecular and cellular studies to preclinical investigations. PLoS
One. 9:e959642014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ouyang B, Knauf JA, Smith EP, Zhang L,
Ramsey T, Yusuff N, Batt D and Fagin JA: Inhibitors of Raf kinase
activity block growth of thyroid cancer cells with RET/PTC or BRAF
mutations in vitro and in vivo. Clin Cancer Res. 12:1785–1793.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ahn SH, Henderson Y, Kang Y, Chattopadhyay
C, Holton P, Wang M, Briggs K and Clayman GL: An orthotopic model
of papillary thyroid carcinoma in athymic nude mice. Arch
Otolaryngol Head Neck Surg. 134:190–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
van Staveren WC, Solís DW, Delys L, Duprez
L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours V, et
al: Human thyroid tumor cell lines derived from different tumor
types present a common dedifferentiated phenotype. Cancer Res.
67:8113–8120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen ST, Shieh HY, Lin JD, Chang KS and
Lin KH: Overexpression of thyroid hormone receptor beta1 is
associated with thyrotropin receptor gene expression and
proliferation in a human thyroid carcinoma cell line. J Endocrinol.
165:379–389. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zito G, Richiusa P, Bommarito A, Carissimi
E, Russo L, Coppola A, Zerilli M, Rodolico V, Criscimanna A, Amato
M, et al: In vitro identification and characterization of
CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma
cell lines. PLoS One. 3:e35442008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Christophe-Hobertus C, Lefort A, Libert F
and Christophe D: Functional inactivation of thyroid transcription
factor-1 in PCCl3 thyroid cells. Mol Cell Endocrinol. 358:36–45.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miccadei S, De Leo R, Zammarchi E, Natali
PG and Civitareale D: The synergistic activity of thyroid
transcription factor 1 and Pax 8 relies on the promoter/enhancer
interplay. Mol Endocrinol. 16:837–846. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nitsch R, Di Dato V, di Gennaro A, de
Cristofaro T, Abbondante S, De Felice M, Zannini M and Di Lauro R:
Comparative genomics reveals a functional thyroid-specific element
in the far upstream region of the PAX8 gene. BMC Genomics.
11:3062010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gilbert-Sirieix M and Massaad-Massade L:
TTF-1: Neither angel nor demon. Med Sci (Paris). 27:183–186.
2011.(In French). View Article : Google Scholar
|
|
49
|
Giannini G, Cabri W, Fattorusso C and
Rodriquez M: Histone deacetylase inhibitors in the treatment of
cancer: Overview and perspectives. Future Med Chem. 4:1439–1460.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li KK, Li F, Li QS, Yang K and Jin B: DNA
methylation as a target of epigenetic therapeutics in cancer.
Anticancer Agents Med Chem. 13:242–247. 2013. View Article : Google Scholar
|
|
51
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Almond JB and Cohen GM: The proteasome: A
novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Provenzano MJ, Fitzgerald MP, Krager K and
Domann FE: Increased iodine uptake in thyroid carcinoma after
treatment with sodium butyrate. Otolaryngol Head Neck Surg.
137:722–728. 2007. View Article : Google Scholar : PubMed/NCBI
|
